Correction: PreImplantation factor (PIF) protects cultured embryos against oxidative stress: relevance for recurrent pregnancy loss (RPL) therapy

Lindsay F. Goodale; Soren Hayrabedyan; Krassimira Todorova; Roumen Roussev; Sivakumar Ramu; Christopher Stamatkin; Carolyn B. Coulam; Eytan R. Barnea; Robert O. Gilbert

doi:10.18632/oncotarget.26505

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: PreImplantation factor (PIF) protects cultured embryos against oxidative stress: relevance for recurrent pregnancy loss (RPL) therapy

PDF | How to cite

Oncotarget. 2018; 9:37344-37344. https://doi.org/10.18632/oncotarget.26505

Metrics: PDF 1254 views | ?

Lindsay F. Goodale^1,6, Soren Hayrabedyan², Krassimira Todorova², Roumen Roussev³, Sivakumar Ramu^3,8, Christopher Stamatkin^3,9, Carolyn B. Coulam³, Eytan R. Barnea^4,5,* and Robert O. Gilbert^1,7,*

¹ Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
² Institute of Biology and Immunology of Reproduction, Bulgarian Academy of Sciences, Sofia, Bulgaria
³ CARI Reproductive Institute, Chicago, IL, USA
⁴ BioIncept, LLC, Cherry Hill, NJ, USA
⁵ Society for the Investigation of Early Pregnancy (SIEP), Cherry Hill, NJ, USA
⁶ Department of Population Health and Reproduction, School of Veterinary Medicine, University of California-Davis, Davis, CA, USA
⁷ Ross University School of Veterinary Medicine, Basseterre, St. Kitts, West Indies
⁸ Promigen Life Sciences, Downers Grove, IL, USA
⁹ Therapeutic Validation Core, Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA
^* These authors have contributed equally to this work

Published: December 18, 2018

This article has been corrected: The correct Author name is given below:

Soren Hayrabedyan

Original article: Oncotarget. 2017; 8:32419-32432. DOI: https://doi.org/10.18632/oncotarget.16028.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26505

Publication Alerts

Oncoscience

Post-Publication Promotion

Corrections:

Correction: PreImplantation factor (PIF) protects cultured embryos against oxidative stress: relevance for recurrent pregnancy loss (RPL) therapy